Lake Street Capital Reaffirms Hold Rating for Checkpoint Therapeutics (NASDAQ:CKPT)

Lake Street Capital reaffirmed their hold rating on shares of Checkpoint Therapeutics (NASDAQ:CKPT) in a research report sent to investors on Monday morning, MarketBeat Ratings reports. The brokerage currently has a $4.10 target price on the stock, down from their prior target price of $7.00.

A number of other equities research analysts also recently weighed in on the stock. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Checkpoint Therapeutics in a research note on Monday, December 16th. D. Boral Capital reissued a “buy” rating and issued a $4.80 price target (down previously from $9.00) on shares of Checkpoint Therapeutics in a report on Monday.

Checkpoint Therapeutics Stock Performance

NASDAQ CKPT opened at $3.98 on Monday. Checkpoint Therapeutics has a twelve month low of $1.38 and a twelve month high of $4.50. The stock has a market capitalization of $194.36 million, a PE ratio of -2.16 and a beta of 1.41. The stock has a 50-day simple moving average of $3.13 and a 200 day simple moving average of $3.10.

Insider Activity

In other news, CFO William Garrett Gray sold 268,432 shares of the company’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $4.01, for a total value of $1,076,412.32. Following the completion of the sale, the chief financial officer now directly owns 1,032,754 shares of the company’s stock, valued at $4,141,343.54. This represents a 20.63 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO James F. Oliviero III sold 10,331 shares of the stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $3.15, for a total transaction of $32,542.65. Following the completion of the sale, the chief executive officer now owns 3,775,019 shares in the company, valued at $11,891,309.85. This represents a 0.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 582,336 shares of company stock valued at $2,156,801 in the last 90 days. 2.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Checkpoint Therapeutics

Large investors have recently bought and sold shares of the company. 683 Capital Management LLC bought a new position in shares of Checkpoint Therapeutics during the fourth quarter worth $522,000. Geode Capital Management LLC increased its position in shares of Checkpoint Therapeutics by 41.2% in the 3rd quarter. Geode Capital Management LLC now owns 427,651 shares of the company’s stock valued at $958,000 after buying an additional 124,787 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Checkpoint Therapeutics during the 4th quarter worth $374,000. Bank of America Corp DE lifted its holdings in Checkpoint Therapeutics by 30,216.8% during the fourth quarter. Bank of America Corp DE now owns 90,041 shares of the company’s stock worth $288,000 after acquiring an additional 89,744 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC grew its stake in Checkpoint Therapeutics by 160.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock valued at $291,000 after acquiring an additional 80,000 shares during the period. Institutional investors own 22.00% of the company’s stock.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.